05 August 2021 | News
Over 3,000 units of transnasal High-Flow Nasal Cannula Oxygen Therapy Device (HFNC) were delivered
Photo Credit: Freepik
Micomme has associated with Polish and Peruvian partners to accomplish the government centralized purchase of 1,600 and 1,500 units of HFNC respectively. Both purchases are strategic material reserves of the local governments. Both purchases were delivered in June 2021.
The leading non-invasive respiratory therapy company in China, Micomme Medical launched its first transnasal High-Flow Nasal Cannula Oxygen Therapy Device (HFNC) OH-70C in 2017. In 2020, Micomme achieved more than 10,000 HFNC installations worldwide (China not included), and helped countries around the world fight against COVID-19 with a production capacity of 500 units per day.
The transnasal High-Flow Nasal Cannula Oxygen Therapy Device is the machine recommended by WHO and related international guidelines for the treatment of patients with COVID-19. It aims to quickly increase the patient's oxygen saturation (SpO2) and improve the symptoms of hypoxia in patients by providing a high-flow air-oxygen mixed gas to patients with a constant temperature, humidity and a constant oxygen concentration.